-

07:41:24 AM

LIVE Real Time PSTV Stock Market News

PSTV - Plus Therapeutics Inc

04/22/21 4:05 PM

Nasdaq : PSTV

Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced

RHEA-AI

neutral

04/08/21 7:30 AM

Nasdaq : PSTV

Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter

RHEA-AI

neutral

03/23/21 7:30 AM

Nasdaq : PSTV

Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies

RHEA-AI

neutral

03/18/21 7:30 AM

Nasdaq : PSTV

Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive

RHEA-AI

neutral

03/03/21 7:30 AM

Nasdaq : PSTV

Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive

RHEA-AI

neutral

02/22/21 4:05 PM

Nasdaq : PSTV

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

- Positive interim data through cohort five for the ReSPECT(TM) Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 - - Completed sixth dosing cohort in ReSPECT(TM) December 2020 - - Management to host conference call today, Monday, February 22 nd , at 5:00 p.m. ET - AUSTIN, Texas,

RHEA-AI

very positive

02/11/21 4:15 PM

Nasdaq : PSTV

Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full

RHEA-AI

neutral

02/11/21 7:30 AM

Nasdaq : PSTV

Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and

RHEA-AI

neutral

01/05/21 4:15 PM

Nasdaq : PSTV

Plus Therapeutics to Participate in Upcoming January Conferences

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will

RHEA-AI

neutral

12/15/20 7:30 AM

Nasdaq : PSTV

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT(TM) Glioblastoma Trial

P lus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in

RHEA-AI

very positive